T2 lesions and rate of progression of disability in multiple sclerosis

European Journal of Neurology

Volumn 17, Issue 12, 2010, Pages 1471-1475

  Mostert, J P ^a,b   Koch, M W ^a   Steen, C ^a   Heersema, D J ^a   De Groot, J C ^a   De Keyser, J ^a,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RIJNSTATE HOSPITAL   (Netherlands)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Disease progression; MRI; Multiple sclerosis; Prognosis

Indexed keywords

ADULT; ARTICLE; BRAIN; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; BRAIN; DISEASE PROGRESSION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX;

EID: 78649546883     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03093.x     Document Type: Article

References (22)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517.
2. Ramsaransing GS, De Keyser J. Benign course in multiple sclerosis: a review. Acta Neurol Scand 2006; 113: 359-369.
3. Ramsaransing GS, De Keyser J. Predictive value of clinical characteristics for 'benign' multiple sclerosis. Eur J Neurol 2007; 14: 885-889.
4. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808-817.
5. Tintore M, Rovira A, Rio J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006; 67: 968-972.
6. Rudick RA, Lee JC, Simon J, Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol 2006; 60: 236-242.
7. Mostert JP, De Groot JC, Ramsaransing GS, Koch MW, De Keyser J. Relationship between the extent of T2 lesions and the onset of secondary progression in multiple sclerosis. Eur J Neurol 2007; 14: 1210-1215.
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
9. Anon. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998; 352: 1491-1497.
10. Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004; 364: 1149-1156.
11. Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63: 1788-1795.
12. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.
13. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006; 129: 584-594.
14. Zivadinov R, Bakshi R. Role of MRI in multiple sclerosis I: inflammation and lesions. Front Biosci 2004; 9: 665-683.
15. De Leeuw FE, De Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001; 70: 9-14.
16. Guttmann CR, Ahn SS, Hsu L, Kikinis R, Jolesz FA. The evolution of multiple sclerosis lesions on serial MR. AJNR Am J Neuroradiol 1995; 16: 1481-1491.
17. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006; 5: 343-354.
18. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-1438.
19. Deluca GC, Williams K, Evangelou N, Ebers GC, Esiri MM. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 2006; 129: 1507-1516.
20. Pascual AM, Martinez-Bisbal MC, Bosca I, et al. Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology 2007; 69: 63-67.
21. Filippi M. Predictive value of MRI findings in multiple sclerosis. Lancet Neurol 2002; 1: 9.
22. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003; 206: 165-171.